摘要
非小细胞肺癌(NSCLC)代表近90%的肺癌。当进行诊断时,很多情况都是晚期或是不能手术,只能采取有限的治疗方式。现有的治疗方法存在不足,急需采用新的治疗策略。新的研究已深入细胞和分子水平,便于研究者发现新的治疗策略。这些定向疗法通过针对特定的与肿瘤进展相关的分子,限制肿瘤的生长。这些策略比化疗和放疗更有效,可以补充现有的治疗方式,增加有益的结果。肺癌则可受益于这种创新的治疗方式。RNA干扰(RNAi)是一种序列特异性的基因沉默机制,自发现以来,广泛应用于癌症治疗中,且作为一个强大的工具。几个在线临床试验已经成功地将其潜在的新的治疗方式进行了演示,包括非小细胞肺癌(NSCLC)的治疗。基于RNAi介导的基因沉默是治疗非小细胞肺癌的一种有效方式,本文研究了与非小细胞肺癌相关的分子变异的治疗效果和有针对性的治疗方法在其治疗中的最新发现。
关键词: 血管再生术、凋亡、单克隆抗体、非小细胞肺癌、核糖核酸干扰、信号转导、小分子靶向治疗。
图形摘要
Current Drug Targets
Title:Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Volume: 16 Issue: 13
Author(s): Ana Vanessa Nascimento, Hassan Bousbaa, Domingos Ferreira and Bruno Sarmento
Affiliation:
关键词: 血管再生术、凋亡、单克隆抗体、非小细胞肺癌、核糖核酸干扰、信号转导、小分子靶向治疗。
摘要: Non-small cell lung cancer (NSCLC) represents close to 90% of all lung cancers. When diagnosed, most cases are on an advanced and inoperable stage, with limited therapeutic options. Existing therapies have shown to be insufficient and novel strategies are urgently necessary. New advances in understanding the disease at cellular and molecular level however have helped researchers in devising novel strategies for therapy. These directed therapies limit cancer growth by targeting specific molecules related with tumor progression. Such strategies have shown to be more effective than chemotherapy and radiotherapy and can be complemented to existing therapeutic paradigm in augmenting beneficial outcome. Lung cancer could benefit from such innovative therapy. RNA interference (RNAi) is a sequence-specific gene silencing mechanism and, since its discovery widespread applications have pointed it as a powerful tool in cancer treatment. Several on-going clinical trials have been successfully demonstrating its potential as a novel therapeutic, including in the treatment of NSCLC. Here, we revise the recent findings concerning the therapeutic effects of molecular variations associated with NSCLC and where targeted therapies stand in its treatment, with special focus on RNAi-mediated gene silencing as a powerful strategy for NSCLC treatment.
Export Options
About this article
Cite this article as:
Ana Vanessa Nascimento, Hassan Bousbaa, Domingos Ferreira and Bruno Sarmento , Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy, Current Drug Targets 2015; 16 (13) . https://dx.doi.org/10.2174/1389450115666140528151649
DOI https://dx.doi.org/10.2174/1389450115666140528151649 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Protein Degradation in the Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism The Roles of Sox Family Genes in Sarcoma
Current Drug Targets Ceramic Nanoparticles: Fabrication Methods and Applications in Drug Delivery
Current Pharmaceutical Design Population Diversity and its Relationship with Infectious and Tumor Diseases
Current Immunology Reviews (Discontinued) Synthetic and Natural Coumarins as Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Therapeutic Effect of Ribbon-Type Nuclear Factor-κB Decoy Oligonucleotides in a Rat Model of Inflammatory Bowel Disease
Current Gene Therapy Recent Patents in Pulmonary Delivery of Macromolecules
Recent Patents on Drug Delivery & Formulation Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells
Current Pharmaceutical Design Design, Synthesis, and Biological Evaluation of C-2 Substituted 3Hthieno[ 2,3-d]pyrimidin-4-one Derivatives as Novel FGFR1 Inhibitors
Medicinal Chemistry Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology The LPS-Pretreated MSCs Supply a Positive Microenvironment for Tumor Cell Proliferation and Clone Formation
Current Protein & Peptide Science Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy The Development of Chromosome Microdissection and Microcloning Technique and its Applications in Genomic Research
Current Genomics Hydroxychloroquine (HCQ) and its Synthetic Precursors: A Review
Mini-Reviews in Organic Chemistry Technology Whitespaces India Should Focus: A Comparative Anti-Cancer Patent Rational Analysis of Indian and International Public Funded Universities
Recent Patents on Anti-Cancer Drug Discovery PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development
Current Drug Targets Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Nucleoside Phosphorylases
Current Organic Chemistry